VYNE Therapeutics (VYNE) Share-based Compensation (QoQ) (2017 - 2025)
VYNE Therapeutics (VYNE) Share-based Compensation (QoQ) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -198.30% |
| Mar 31, 2025 | 9.16% |
| Dec 31, 2024 | -4.77% |
| Sep 30, 2024 | -17.06% |
| Jun 30, 2024 | -10.15% |
| Mar 31, 2024 | 453.37% |
| Dec 31, 2023 | 110.45% |
| Sep 30, 2023 | -294.41% |
| Jun 30, 2023 | 2.34% |
| Mar 31, 2023 | 126.50% |
| Dec 31, 2022 | -200.72% |
| Sep 30, 2022 | 468.62% |
| Jun 30, 2022 | -197.42% |
| Mar 31, 2022 | 495.33% |
| Dec 31, 2021 | 103.57% |
| Sep 30, 2021 | -320.88% |
| Jun 30, 2021 | -22.15% |
| Mar 31, 2021 | 961.74% |
| Dec 31, 2020 | -75.97% |
| Sep 30, 2020 | 871.77% |